Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06018558 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

Study acronym: ArMaDa
StatusActive, Not Recruiting
PhasePhase 1/2
SponsorOcugen
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from May 29, 2026 to Feb 3, 2030
    • Primary completion date changed from estimate of Feb 17, 2026 to Feb 3, 2026
    v11
  2. 2 versions Re-verified since Jun 16, 2025, no change to tracked fieldsv9-v10
  3. Trial status: Recruiting to Active, Not Recruitingv8 Show 7 more changesShow less
    • Enrollment target: estimated 63 to confirmed 60
    • Study sites: 9 to 12
    • Primary completion date: Sep 23, 2025 to Feb 17, 2026
    • Study completion date: Sep 23, 2025 to May 29, 2026
    • Start date: Aug 23, 2023 to Feb 23, 2023
    • Eligibility criteria expanded, about 11 words
    • Study description expanded, about 4 words
  4. Re-verified, no change to tracked fieldsv7
  5. Study sites: 6 to 9
    • Eligibility criteria revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 3 to 6
    • Eligibility criteria expanded, about 73 words
    v5
  2. Study sites: 2 to 3v4
  3. Primary completion date: Mar 30, 2026 to Sep 23, 2025
    • Study completion date: May 30, 2026 to Sep 23, 2025
    v3
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ocugen
6 trials monitored
See all monitored trials
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.
Trial Details
NCT Number NCT06018558
Lead Sponsor Ocugen
Conditions
(from sponsor)		 Geographic Atrophy
Related terms Geographic Atrophy
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov